These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

Regeneron Pharmaceuticals (REGN) reported robust second-quarter results, with adjusted EPS of $12.89 (up 12% YoY) and sales of $3.68 billion (up 4% YoY), both significantly exceeding consensus estimates. This strong performance was attributed to growth in key products like EYLEA HD and Dupixent, alongside recent regulatory approvals. Following the upbeat report, REGN shares saw a modest gain, and multiple analysts, including Guggenheim and Morgan Stanley, raised their price targets, signaling continued positive sentiment.

Analysis

Regeneron Pharmaceuticals delivered a robust second-quarter performance, significantly outperforming market expectations. The company reported adjusted earnings of $12.89 per share, a 12% year-over-year increase that surpassed the consensus estimate of $8.57, while sales grew 4% to $3.68 billion, also beating the forecast of $3.29 billion. This top-line strength was attributed to strong U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo, supplemented by multiple recent regulatory approvals. Despite the strong quarterly results, the company's 2025 guidance for gross margins was slightly narrowed, with the top end of the range for both GAAP and adjusted margins being modestly reduced to approximately 83% and 86% respectively. In response to the earnings beat, Wall Street analysts from firms including Guggenheim and Morgan Stanley raised their price targets, signaling confidence in the company's trajectory, although the stock's modest 0.9% gain suggests a more measured market reaction.

Key Decisions for Investors

• The significant beat on both revenue and earnings, driven by core product growth in EYLEA HD and Dupixent, provides strong fundamental support for a bullish stance on the stock.
• Investors should monitor future margin performance closely, as the slight tightening of the 2025 gross margin forecast could signal potential, albeit minor, cost pressures or a shift in product mix.
• Given the positive analyst price target revisions but the relatively muted 0.9% stock price reaction, there may be an opportunity for accumulation before the market fully prices in the strong quarterly results.